Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 10/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22523749 | 0.84 | PTPN11 (0.35) | SLC6A4SLC6A3PTPN11KCNH2 | |
| SCHEMBL24335988 | 0.80 | OPRM1 (0.36) | SLC6A4SLC6A3SLC6A2CYP2D6DRD3 | |
| SCHEMBL21940874 | 0.78 | PTPN11 (0.39) | SLC6A4SLC6A3SLC6A2PTPN11KCNH2 | |
| SCHEMBL21940872 | 0.78 | PTPN11 (0.39) | SLC6A4SLC6A3SLC6A2PTPN11KCNH2 | |
| SCHEMBL24388823 | 0.76 | PTPN11 (0.47) | PTPN11KCNH2 | |
| SCHEMBL23046087 | 0.76 | PTPN11 (0.47) | PTPN11KCNH2 | |
| SCHEMBL21940659 | 0.76 | PTPN11 (0.47) | PTPN11KCNH2 | |
| SCHEMBL24635820 | 0.75 | HTR2A (0.35) | PTPN11 | |
| SCHEMBL23023952 | 0.75 | HTR2A (0.35) | PTPN11 | |
| SCHEMBL24672327 | 0.75 | HTR2A (0.35) | PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340576-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | PTPRCAP, PTPN22, PTPN1 | SLC6A4 4652/4885SLC6A3 4441/4885SLC6A2 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.